These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2208122)

  • 1. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
    Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR
    Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
    Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
    Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
    King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
    Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.
    Braslawsky GR; Kadow K; Knipe J; McGoff K; Edson M; Kaneko T; Greenfield RS
    Cancer Immunol Immunother; 1991; 33(6):367-74. PubMed ID: 1878890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier.
    Shih LB; Goldenberg DM; Xuan H; Lu H; Sharkey RM; Hall TC
    Cancer Res; 1991 Aug; 51(16):4192-8. PubMed ID: 1868440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
    Sinkule JA; Rosen ST; Radosevich JA
    Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-(2-pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates.
    Ansell SM; Tardi PG; Buchkowsky SS
    Bioconjug Chem; 1996; 7(4):490-6. PubMed ID: 8853463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro cytotoxicity of the conjugate adriamycin with anti-sarcoma monoclonal antibody 19-24.
    Mohamed G; Kuzmanoff KM; Stastny JJ; Das Gupta TK
    Anticancer Res; 1992; 12(2):529-32. PubMed ID: 1580569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
    Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
    Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New hydrazone derivatives of adriamycin and their immunoconjugates--a correlation between acid stability and cytotoxicity.
    Kaneko T; Willner D; Monkovíc I; Knipe JO; Braslawsky GR; Greenfield RS; Vyas DM
    Bioconjug Chem; 1991; 2(3):133-41. PubMed ID: 1932212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation and in vitro activity of monoclonal antibody-pharmorubicin immunoconjugates].
    Xu FH; Jiang XT
    Yao Xue Xue Bao; 1996; 31(8):632-6. PubMed ID: 9772712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of CC49-doxorubicin immunoconjugates.
    Johnson DA; Briggs SL; Gutowski MC; Barton R
    Anticancer Res; 1995; 15(4):1387-93. PubMed ID: 7654026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity.
    Ogden JR; Leung K; Kunda SA; Telander MW; Avner BP; Liao SK; Thurman GB; Oldham RK
    Mol Biother; 1989; 1(3):170-4. PubMed ID: 2604916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin.
    Willner D; Trail PA; Hofstead SJ; King HD; Lasch SJ; Braslawsky GR; Greenfield RS; Kaneko T; Firestone RA
    Bioconjug Chem; 1993; 4(6):521-7. PubMed ID: 7508268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.